Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMC-001 manganese-based oral contrast for liver MRI in patients with liver metastases (Phase II)
2005-001254-25Phase 2Completed
- Sponsor
- Ascelia Pharma
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CMC 001 in hepatic metastasis (2 arms), sponsored by Ascelia Pharma. Primary endpoints: Diagnostic efficacy of CMC-001 and Time-response of CMC-001. Started Oct 2005; status: completed.
02
Drugs
CMC 001
03
Conditions
hepatic metastasis
Beyond the preview
Go deeper on 2005-001254-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001254-25.